Home>Topics>>Alectinib cleared in Japan

Alectinib cleared in Japan

SeekingAlpha.com: SA Currents

Fri, 4 Jul 2014

The Japanese Ministry of Health, Labor and Welfare approves Roche's ( OTCQX:RHHBY ) alectinib for the treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). The product will be available for sale later this year. In June 2013, ...

Related Videos

  1. Stattman: There's a Lot to Like in Japan

    Mon, 23 Jun 2014

    Very attractive valuations compared to the U.S. market and an increased focus on shareholder value from Japanese companies combine to make Japanese equities attractive--but mind your yen exposure, says Dennis Stattman, manager of the Gold-rated BlackRock Global Allocation Fund.

Content Partners